via Johns Hopkins University
Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn’s disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.
But the costly, time-consuming manufacturing process to produce antibodies prevents these treatments from being accessible to most patients.
Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering at Penn State, has identified a new method to manufacture antibodies, which could drive down the production cost. His research results were recently published in Biotechnology Progress.
“If you look at the top 10 best-selling medications, by annual sales, eight are in the category of monoclonal antibodies,” Zydney said. “And every year, individuals and insurance companies spend upwards of $100 billion on antibodies, with costs to treat a single patient often exceeding $50,000. There remains a huge unmet need for these products in treating a growing range of diseases.”
Known as precipitation, Zydney’s new protein purification process involves adding zinc chloride and polyethylene glycol, a water-soluble polymer, to a solution containing the antibody. This causes the antibody to precipitate so that the impurities can be washed away.
Though the precipitation process has been used for 70 years in blood plasma processing, it has never been used for the commercial production of antibodies, according to Zydney.
“To precipitate means ‘to come out’ of a solution in a solid form,” he said. “For example, when you put salt in warm water, it dissolves. But if you put a lot of salt into cold water, some of that salt will remain as solid crystals. In the same way, proteins would normally dissolve in a solution, but you can find certain conditions where they come out as solid.”
Zydney explained that the zinc chloride used in precipitation is a simple salt, making it much cheaper than other purification methods. It also saves time, as it is possible to yield large quantities of proteins in short periods of time.
Currently, antibodies are produced using a process called Protein A affinity chromatography, where the antibody binds to Protein A, which is immobilized in a chromatography column. The impurities can be washed away from the bound antibody, after which the pH level is adjusted to recover the purified antibody product. A single Protein A chromatography column can cost more than $10 million.
“That is just one step in the current manufacturing process, and it is what makes antibody manufacturing so expensive,” Zydney said. “All of the major biotechnology companies are big players in this space.”
The precipitation process eliminates the need for the costly chromatography process, as antibodies are purified directly from the solution by filtration through hollow fiber membranes.
“What we do in our research group is relatively small scale,” He said. “But the precipitation process has the potential to be easily scaled up, potentially enabling biopharmaceutical companies to produce lower-cost antibodies for the patients who need them.”
Todd Przybycien, professor of chemical and biological engineering at Rensselaer Polytechnic Institute, contributed to this research.
Original Article: Antibody injections could become more affordable with new production method
More from: Pennsylvania State University | Rensselaer Polytechnic Institute
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibody injections
- Lower Dose MPox Vaccine: Safe With Equal Six-Week Antibody Response
Lower dose of monkeypox vaccine is found to be safe with equal six-week antibody response, promising for vaccination strategies.
- CDSCO panel rejects Pfizer Products India Local Clinical Trial Waiver Proposal for Elranatamab solution for injection
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an ...
- Monoclonal antibody offers strong malaria protection in children
Today in the New England Journal of Medicine a study demonstrates that a single subcutaneous (just-under-the-skin) injection of an experimental malaria monoclonal antibody offered up to 77% protection ...
- Experimental NIH malaria monoclonal antibody protective in Malian children
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results ...
- Experimental NIH Antibody Protects Children From Malaria in Clinical Trial
A new study reports a single dose of a malaria antibody was 77% effective in protecting children in Mali from malaria, marking a significant step in malaria prevention efforts. One injected dose of an ...
Go deeper with Google Headlines on:
Antibody injections
[google_news title=”” keyword=”antibody injections” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibody manufacturing
- News - Pierre Fabre
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The firm is applying its proprietary Cloudbreak platform to ...
- Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
German biotech Immatics has two major data readouts due 2H24, and a pivotal study initiation in melanoma - the risk reward is attractive. Explore more here.
- Roche: Improved biomanufacturing efficiency drove $1.2bn Vacaville sale
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a California facility to Lonza.
- Germany's Merck breaks ground on $321m biomanufacturing center
Merck KGaA has begun construction on an 18,000 square-meter research center at its global headquarters in Darmstadt, Germany.
- Vietnam Diagnostic Specialty Antibodies Market Marvels Diving into the Dazzling World of Latest Trends
Report Ocean’s latest analysis delves into the “Vietnam Diagnostic Specialty Antibodies Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, ...
Go deeper with Google Headlines on:
Antibody manufacturing
[google_news title=”” keyword=”antibody manufacturing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]